Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 4/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | QDPR | P09417 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 8/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3005989 | 0.79 | CSF1R (0.41) | CSF1RQDPRHTR2CSLC18A3SIGMAR1 | |
| SCHEMBL18240960 | 0.77 | CSF1R (0.45) | CSF1RKITSLC18A3TLR9TLR8 | |
| SCHEMBL4380557 | 0.74 | CSF1R (0.49) | CSF1RKITTLR9TLR8TLR7 | |
| SCHEMBL4979196 | 0.74 | CSF1R (0.49) | CSF1R | |
| SCHEMBL4057863 | 0.74 | CSF1R (0.49) | CSF1RKITHDAC1HDAC2TLR9 | |
| SCHEMBL2914743 | 0.74 | CSF1R (0.49) | CSF1RKITQDPRHTR2CCYP2C9 | |
| SCHEMBL3164538 | 0.73 | CSF1R (0.48) | CSF1RKITQDPRHTR2CCYP2C9 | |
| SCHEMBL18240980 | 0.72 | CSF1R (0.41) | CSF1RKITCYP2C9TLR9TLR8 | |
| SCHEMBL2914647 | 0.71 | CSF1R (0.43) | CSF1RKITCYP2C9HDAC1HDAC2 | |
| SCHEMBL2097686 | 0.70 | QDPR (0.49) | QDPRHTR2CSLC18A3SIGMAR1TLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222298-A1 | USE OF CFMS INHIBITOR FOR TREATING OR PREVENTING BONE CANCER AND THE BONE LOSS AND BONE PAIN ASSOCIATED WITH BONE CANCER | Janssen Pharmaceutica N.V. (BE) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009058801-A1 | USE OF CFMS INHIBITOR FOR TREATING OR PREVENTING BONE CANCER AND THE BONE LOSS AND BONE PAIN ASSOCIATED WITH BONE CANCER | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-07 | — | — | WO | disclosed |
| EP-1951234-A2 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007048088-A2 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-26 | — | — | WO | disclosed |